ECRAID-Prime

ECRAID-Prime („European Clinical Research Alliance on Infectious Diseases: Primary Care adaptive platform trial for pandemics and epidemics“)

ECRAID-Prime is a randomized controlled intervention study that is investigating various active substances for the treatment of respiratory tract infections in adult patients in 6 European countries as part of a platform study.

Respiratory tract infections can be caused by a variety of pathogens, such as the SARS-CoV-2 virus, but also by influenza pathogens and other viruses and, less frequently, bacteria. Especially in the colder months, respiratory tract infections are a frequent cause for consultation in GP practices.

The University Hospital of Würzburg is a study center of the EU-funded research network ECRAID-Prime through the Department of General Medicine. The aim of the study is to find new therapies for respiratory tract infections that can help

• speed up recovery
• reduce the severity of symptoms
• reduce the viral load and thus possibly prevent infection

Study participants will receive either the study drug (nitric oxide) and usual care or a comparator drug (saline) in the form of a nasal spray and usual care or usual care only. Each study participant is then observed for 28 days using a diary and questioned about the course of the disease after 3 and 6 months. The study duration for participants is 6 months.

Potentially suitable participants are 18 years old or older and have symptoms of a respiratory infection, e.g. sore throat, cough, fatigue, headache, fever, cold: Sore throat, cough, fatigue, headache, fever, runny nose. The symptoms should have been present for no more than 4 days.

Please do not hesitate to contact us for further information.